Company Overview and News
2018-09-20 investorplace - 1
There has been a big disparity in the performance of big oil stocks so far in 2018. The price of oil itself has been waffling back and forth between upward cycles and downward ones with a slight upward skew. There have been events and conditions that have restricted oil output from some countries, while others have boosted production in order to meet worldwide demand.
COP HES CVX
The Fidelity MSCI Energy Index ETF (FENY - Free Report) was launched on 10/21/2013, and is a passively managed exchange traded fund designed to offer broad exposure to the Energy - Broad segment of the equity market.
COP FSTA VDE FENY XOM CVX FDIS LB
Shares of ConocoPhillips (COP - Free Report) have scaled a new 52-week high of $75.73 in yesterday’s trading session, before eventually closing a tad lower at $75.04, generating a healthy year-to-date rate of around 36.7%. The stock displays an impressive price movement both in absolute and relative terms. The company has had a great run on the bourses over a year, with its shares rallying in excess of 56.
COP MRO OXY EOG
CNOOC Limited (CEO - Free Report) recently announced that the company has started production at its Penglai 19-3 oilfield 1/3/8/9 comprehensive adjustment project, one of the biggest offshore oilfields in China. The project is located 80 kilometers southeast from Penglai city and 216 kilometers northwest from Tanggu, in the south central part of Bohai Sea.
COP RGCO CEO
ConocoPhillips (COP - Free Report) recently agreed to partner with liquefied natural gas (LNG) engineer KBR, Inc. (KBR - Free Report) to work on designing a mid-scale LNG train. The companies expect the design to be ready for LNG projects that will start in 2019.
COP TXN MDPEB MDP RGCO
KBR, Inc. (KBR - Free Report) has collaborated with ConocoPhillips (COP - Free Report) to develop a low-cost mid-scale liquefied natural gas (“LNG”) train that should be accessible to new LNG projects starting in 2019. The companies plan to complete a front-end engineering and design (“FEED”) quality reference design for a mid-scale capacity liquefied natural gas train. The train, with a capacity between 1.
COP JEC FIX MDPEB MDP
In 2017, the S&P 500 returned 21.70%, including dividends paid, but the energy sector did not get the memo. Last year, the Energy Select Sector SPDR (NYSEARCA:XLE), the largest energy exchange-traded fund (ETF) by assets, lost 0.9%, marking the fifth time in the previous six years that the benchmark energy ETF trailed the S&P 500.
COP PSCF XOM CVX ENFR EOG
Crude oil was trading right around $69 a barrel early on Thursday. Over the past month, crude has been up and down, reaching as high as about $73 and as low as $65, but the current crude price still pales in comparison to what it was in 2014.
COP BP XOM CVX BP BPAQF OXY PBR BP.A BP.B
August marks the 10th month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $1,665.95.
SOJA GIS XOM IDCC SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI WLKP ENB ETP HP ORI SPG WPC ADM
On the news front, offshore driller Transocean Ltd. (RIG - Free Report) agreed to acquire smaller peer Ocean Rig UDW, Inc. for $2.7 billion, while supermajor Chevron Corp. (CVX - Free Report) scored a big legal victory over pollution claims in Ecuador that protects the company from having to pay $9.5 billion fine.
SLB MPLX LB MPC ORIG COP BHI ETP CVX SCL SLB MMP RIG SGAZF
Exxon Mobil Corporation (XOM - Free Report) has agreed to the terms and conditions of Alaska Gasoline Development Corp (AGDC) for sale of its natural gas from the Prudhoe Bay and Point Thomson fields. AGDC is a state-owned entity leading the development of the Alaska LNG Project. The deal follows closely on the heels of a similar commitment made by BP plc (BP - Free Report) , also a major North Slope gas owner, in May.
COP XOM MPC 0386
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to COP / ConocoPhillips on message board site Silicon Investor.
as of ET